Komori
Perseus Proteomics (4882) · InitiativeMore Specific Human Capital Strategy

Securing and Developing Highly Skilled R&D Personnel and Building the Organisational Structure

First written in FY2021. 6 of 10 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2026.

10entries
6years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021 – FY2023AdvancedFY2024-Q1 – FY20252021: 120212022: 020222023: 220232024: 120242025: 120252026: 52026
Same theme, other companies
Strengthening R&D staffing and development capabilitiesA theme 51 companies write about · 0 as a headwind · 52 as a tailwind

The whole theme swung hardest in 2026: 3 of 34 companies on the "Worse" side.

7 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 51 companies compared. The sentences above are computed from all 51.
Full recordFilings, disclosures and news, newest first
  1. FY2026More Specific Human Capital StrategyAnnual report

    「To compete successfully in the development of new antibody drugs, we are actively recruiting researchers from Japan and overseas who hold doctoral degrees or have outstanding achievements and capabilities in drug discovery research and development. To retain employees, we have also established incentive programs linking individual performance with medium- to long-term increases in corporate value, including individual performance-linked compensation and bonus plans and stock-based stock options.」

    The company has made its human resources strategy more specific by combining the recruitment of outstanding researchers with their development through research presentations, academic conference participation and joint research, as well as retention measures involving performance-linked compensation and bonuses and stock-based stock options.
  2. FY2025AdvancedAnnual report

    「As part of our diversity initiatives, we hired 2 foreign nationals in April 2024 and 1 in April 2025.」

    To secure a diverse workforce, the company hired 1 additional foreign national in April 2025.
  3. FY2024AdvancedAnnual report

    「As part of our diversity initiatives, we hired 2 foreign nationals in April 2024.」

    To promote workforce diversity, the company hired 2 foreign nationals in April 2024.
  4. FY2024-Q1AdvancedAnnual report

    「To advance our business, we have worked to secure outstanding personnel and have hired 7 researchers since the listing, allocating more funding than initially planned.」

    Since listing, the company has hired 7 researchers and increased the amount allocated to research and development operating expenses above the initial plan.
  5. FY2023RestatedAnnual report

    「We will actively recruit outstanding personnel and work to develop and expand our pipeline. We will also continue creating a comfortable and rewarding workplace and strengthen our corporate foundation by supporting employee growth.」

    The company has reaffirmed its policy of strengthening its research and development foundation through recruiting outstanding personnel, creating a comfortable workplace and supporting employee growth.
  6. FY2021First statedAnnual report

    「We will therefore actively recruit outstanding personnel and build an organisational research and development structure capable of delivering research results efficiently.」

    The company plans to develop a research and development structure capable of delivering results efficiently through recruitment.
Moved together

"Development of the PPMX-T004 ADC and licensing to FUJIFILM" moved the same way as this thread, in the same document, in 4 of its 10 moves.

443333★123456
  1. ★This thread
  2. 1Development of the PPMX-T004 ADC and licensing to FUJIFILM4×
  3. 2Securing R&D Funding Through Partnerships, Grants and Investor Fundraising4×
  4. 3Drug Discovery through Joint Research with Universities and Research Institutions and Expansion of Contract Research3×
  5. 4Research on expanding PPMX-T003 indications to hematologic and solid cancers3×
  6. 5Expansion of antibody research support and sales of antibodies and reagents3×
  7. 6Redevelopment Following the Return of the License Rights for PPMX-T002 and PPMX-T0043×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Perseus Proteomics yet. It last moved in the General Meetings of Shareholders of 2026-06-03: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Securing and Developing Highly Skilled R&D Personnel and Building the Organisational Structure | Perseus Proteomics Inc. (4882) | Komori